Cholecystokinin and pain: a review.

Abstract

The recent discovery that cholecystokinin (CCK) is present in the nervous system has prompted studies that have nearly proven its neurotransmitter status. Pain modulation appears to be a major effect of CCK and proglumide, its antagonist. CCK's inhibitory effect and proglumide's potentiating effect on opiate analgesia may have clinical application; proglumide's inhibitory effect on opiate tolerance may help in management of chronic pain. More research is required before the CCK/opiate interaction can be exploited on a large scale to relieve pain.

• Authors: J W McRoberts
• Journal: Anesthesia progress (Anesth Prog) 1986 Mar-Apr Vol. 33 Issue 2 Pg. 87-90 ISSN: 0003-3006 [Print] United States
• PMID: 2872841 (Publication Type: Journal Article, Review)

Chemical References

• Neurotransmitter Agents
• Receptors, Opioid
• Cholecystokinin
• Proglumide

Topics

• Cholecystokinin (analysis, antagonists & inhibitors, physiology)
• Humans
• Neurotransmitter Agents
• Pain (drug therapy, physiopathology)
• Periaqueductal Gray (analysis)
• Proglumide (pharmacology)
• Receptors, Opioid (physiology)